Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Jun;20(2):148-54.
doi: 10.4104/pcrj.2011.00022.

Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma

Affiliations
Comparative Study

Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma

Angkana Roy et al. Prim Care Respir J. 2011 Jun.

Abstract

Aim: To compare inhaled corticosteroid (ICS) inhaler type with user technique and ICS medication adherence among adults with asthma.

Methods: We classified 270 adults into two groups by ICS device type: metered-dose inhaler (MDI) or dry powder inhaler (DPI). Inhaler technique was assessed using standardised checklists. Medication adherence was evaluated using the Medication Adherence Report Scale (MARS). Differences in inhaler technique and MARS score among patients using MDIs versus DPIs were evaluated.

Results: Univariate analysis showed no difference in technique scores between the groups (p=0.46), but better ICS adherence among DPI users (p=0.001). In multivariable analysis, DPI use remained significantly associated with higher rates of adherence (OR 2.2; 95% CI 1.2 to 3.8) but not with inhaler technique (-0.2; 95% CI -0.5 to 0.1) after adjusting for potential confounders.

Conclusions: Type of inhaler device appears to be associated with adherence to asthma controller medications. Prospective studies are needed to elucidate further the potential effect of the type of ICS delivery device on asthma self-management.

PubMed Disclaimer

Conflict of interest statement

Dr Juan Wisnivesky has received a research grant from GlaxoSmithKline and is a member of the research advisory board of EHE International. The other authors have no conflicts of interest to disclose

Comment in

Similar articles

Cited by

Publication types

Substances